| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/19/2004 | US6805868 Isolated, recombinant polypeptide comprising member selected from specified amino acid sequence and immunogenic fragment of at least 15 contiguous amino acids of that sequence; induces antibody or t-cell mediated immune response when administered |
| 10/19/2004 | US6805865 Compositions and methods for treating cancer and hyperproliferative disorders |
| 10/19/2004 | US6805864 Type I angiotensin II receptor specific monoclonal antibodies and hybridomas |
| 10/19/2004 | US6805863 Comprises antibodies/proteins providing inhibition of prothrombinase; treatment and prevention of bacterial and viral infections, allograft/xenograft rejection, glomerulo-nephritis, cancer, gastrointestinal diseases, and fetal loss |
| 10/19/2004 | US6805862 Generating in subject immune response against ganglioside gd3 by administering antiidiotypic antibody bec-2 (atcc no. hb 10153) |
| 10/19/2004 | CA2323096C Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| 10/17/2004 | CA2463827A1 Methods and compositions for controlled release of bioactive compounds |
| 10/14/2004 | WO2004087921A1 Human solid cancer antigen peptides, polynucleotides encoding the same and utilization thererof |
| 10/14/2004 | WO2004087899A1 Method for obtaining regulating dendritic cells and t cells |
| 10/14/2004 | WO2004087886A2 Modified adenoviral e1a constructs and methods of use thereof |
| 10/14/2004 | WO2004087876A2 Use of red blood cells to facilitate cell activation |
| 10/14/2004 | WO2004087864A2 Amended recombinant cells (arcs) for the production and delivery of antiviral agents, adjuvants and vaccine accelerants |
| 10/14/2004 | WO2004087767A1 Polypeptide |
| 10/14/2004 | WO2004087760A1 Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions |
| 10/14/2004 | WO2004087749A2 Nontypeable haemophilus influenzae virulence factors |
| 10/14/2004 | WO2004087748A1 Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same |
| 10/14/2004 | WO2004087746A2 Staphylococcus epidermidis antigens |
| 10/14/2004 | WO2004087207A2 Method for inducing apoptosis and aneuploidy regression in cancer cells |
| 10/14/2004 | WO2004087204A2 Microfluidized oil-in-water emulsions and vaccine compositions |
| 10/14/2004 | WO2004087203A2 Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| 10/14/2004 | WO2004087202A2 Pharmaceutical composition comprising a macrolide immunomodulator |
| 10/14/2004 | WO2004087178A1 A formulation comprising a bacterial strain |
| 10/14/2004 | WO2004087062A2 Compositions and methods involving respiratory syncytial virus subgroup b strain 9320 |
| 10/14/2004 | WO2004087058A2 Targeted mhc class i alpha3 vaccine delivery systems |
| 10/14/2004 | WO2004087047A2 Mutants of replication competent vaccinia virus |
| 10/14/2004 | WO2004075811A3 Subcutaneously-administered ganglioside-based vaccine compositions |
| 10/14/2004 | WO2004043988A3 Ptprk immunogenic peptide |
| 10/14/2004 | WO2004043376A3 Compositions and methods for treating or preventing pneumococcal infection |
| 10/14/2004 | WO2004031775A3 Method for treating or preventing metastasis of colorectal cancers |
| 10/14/2004 | WO2004031774A3 Method for treating or preventing metastasis of colorectal cancers |
| 10/14/2004 | WO2004024063A3 Compositions and methods for the diagnosis and treatment of tumor |
| 10/14/2004 | WO2004021010A3 Method of diagnosing colon and gastric cancers |
| 10/14/2004 | WO2004019866B1 Compositions and methods for treating cardiovascular disease |
| 10/14/2004 | WO2004016769A3 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| 10/14/2004 | WO2004009632A3 Method for the production of an immunostimulating mucin (muc1) |
| 10/14/2004 | WO2004007679A3 Dendritic cell pontentiation |
| 10/14/2004 | WO2003091395A3 Inhibition of immune complex formation |
| 10/14/2004 | WO2003075945A3 Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis |
| 10/14/2004 | WO2003065985A3 Uses of mammalian cytokine; related reagents |
| 10/14/2004 | WO2003061595A3 Antibodies against and compositions containing new amphetamine derivatives |
| 10/14/2004 | WO2003031475A8 Antibodies against kdr, their production and uses |
| 10/14/2004 | WO2002030980A8 Use of anti-human integrin alpha d antibodies to treat spinal cord injury |
| 10/14/2004 | US20040204581 Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immonogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens |
| 10/14/2004 | US20040204578 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 10/14/2004 | US20040204568 Comprises nucleotide sequences coding cell adhesion molecules for use in the diagnosis, prevention and treatment of autoimmune and cell proliferative disorders |
| 10/14/2004 | US20040204565 Use of multivalent chimeric peptide-loaded, MHC/IG molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| 10/14/2004 | US20040204361 Kdel receptor inhibitors |
| 10/14/2004 | US20040204359 Methods and compositions in treating pain and painful disorders using 16386,15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620 |
| 10/14/2004 | US20040203131 diagnosis of transmissible spongiform encephalopathies (TSEs) especially in an immunoassay, as well as its use as an immunogen; genetic engineering |
| 10/14/2004 | US20040203124 Electrodes coated with treating agent and uses thereof |
| 10/14/2004 | US20040203118 Polynucleotides and polypeptides of the IFNalpha-14 gene |
| 10/14/2004 | US20040203116 IL-1 eta DNA and polypeptides |
| 10/14/2004 | US20040203115 Methods and compositions for production and purification of recombinant staphylococcal enterotoxin b (rseb) |
| 10/14/2004 | US20040203111 UDP-N-acetylglucosamine: galactose-B1,3-N-acetylgalactosamine-a-R/ (GlcNAc to GalNAc) B1-6 N- acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203108 use as a carrier for a conjugate, particularly in combination with a polysaccharide, and a process for producing the peptide as well as vaccines comprising said peptide |
| 10/14/2004 | US20040203098 Compounds and methods for modulating activation of NF-kappaB |
| 10/14/2004 | US20040203097 Kinases and phosphatases |
| 10/14/2004 | US20040203093 Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof |
| 10/14/2004 | US20040203092 UDP-N-acetylglucosamine:galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1-6 N-acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203084 protein antigens for producing neutralizing antibodies; biodrugs |
| 10/14/2004 | US20040203066 Identifying modulator of progression elevated gene-3 (PEG-3) for use in treatment and prevention of antitumor/antiproliferative/antisense agents; peptide mimetic |
| 10/14/2004 | US20040203065 Novel method of diagnosing, monitoring, staging, imaging and treating lung cancer |
| 10/14/2004 | US20040203051 Nucleotide sequences coding two or more tumor associated antigens for use in identify modulators of major histocompatibility complex; preventing infections |
| 10/14/2004 | US20040203039 Attenuated salmonella SP12 mutants as antigen carriers |
| 10/14/2004 | US20040203014 Neurotransmisson-associated proteins |
| 10/14/2004 | US20040202720 Delivery of immune response modifier compounds using metal-containing particulate support materials |
| 10/14/2004 | US20040202680 made of a biodegradable poly( alpha -hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, or a polyanhydride, formed using cationic, anionic, or nonionic detergents the surfaces of which adsorb biologically active macromolecules, such tumor antigens; vaccine delivery |
| 10/14/2004 | US20040202679 truncated papillomavirus L1 protein consisting of an amino acid sequence having one or more carboxy terminal amino acid residues deleted from a full length L1 amino acid sequence, and amino acid residues from a second protein replacing deleted amino acid residues in the truncated L1 protein. |
| 10/14/2004 | US20040202678 attenuated, having a mutation in a gene encoding a repeat in toxin |
| 10/14/2004 | US20040202676 using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process |
| 10/14/2004 | US20040202675 use of K12 as a non-antigen specific activator of immune function. |
| 10/14/2004 | US20040202674 zona pellucida polypeptide, and/or a variant, from a carnivorous mammal, useful in reducing fertility of cats and/or dogs. |
| 10/14/2004 | US20040202673 designed to elicit high level of antibodies for immunotherapy or immunomodulation of the body regulatory processes. |
| 10/14/2004 | US20040202672 Dermatomycosis vaccine |
| 10/14/2004 | US20040202671 helminths obtained from preparatory animals raised in a specific human pathogen-free environment used to treat an excessive immune response including an aberrant/enhanced Th1 response, e.g., Crohn's disease and ulcerative colitis |
| 10/14/2004 | US20040202670 containing a biofilm peptide, especially a Haemophilus influenzae biofilm peptide, used to prevent otitis media |
| 10/14/2004 | US20040202669 Immunogenic compositions containing phospholipid |
| 10/14/2004 | US20040202668 combination vaccine kit with one container of acellular pertussis toxoid and FHA, tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen, and inactivated polio virus, and a second container of conjugates of a carrier protein and a capsular polysaccharide from Streptococcus pneumoniae |
| 10/14/2004 | US20040202667 also use in the development of antimalarial drugs and antibodies directed against these Plasmodium proteins. |
| 10/14/2004 | US20040202666 Anti-cancer anthracycline drug-antibody conjugates |
| 10/14/2004 | US20040202665 agent, such as anticancer, antimetastasis, antileukemia, antidisease, antiadhesion, antithrombosis, antirestenosis, antiautoimmune, antiaggregation, antibacterial, antiviral, or antiinflammatory agents (preferably an anthracycline) and an antibody; the agent may be conjugated to the antibody |
| 10/14/2004 | US20040202662 Humanised antibodies |
| 10/14/2004 | US20040202660 orally administering an immunoglobulin to modulate serum IgG and/or TNF- Delta levels for treatment of autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans. |
| 10/14/2004 | US20040202659 A polypeptide encoded by a nucleic acid that encodes a heavy chain, which is able to bind to GPIIb/IIIa, of a human antibody and comprising a CDR3 region; diagnosis, treatment or prevention of autoimmune thrombocytopenic purpura; modulating blood coagulation |
| 10/14/2004 | US20040202657 Humanized anti-CD3 specific antibodies |
| 10/14/2004 | US20040202651 Uses of anti-insulin-like growth factor 1 receptor antibodies |
| 10/14/2004 | US20040202650 Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies |
| 10/14/2004 | US20040202648 Vaccines |
| 10/14/2004 | US20040202647 T cell line specific for a nitrotyrosine-containing compound; antibody specific for a self-antigen comprising a tyrosine to nitrotyrosine conversion; prevention and treatment of autoimmune diseases, infectious diseases and cancer through the recognition of compounds containing nitrated tyrosine residues |
| 10/14/2004 | US20040202646 Bifunctional glycoproteins having a modified carbohydrate complement and their use in tumor-selective therapy |
| 10/14/2004 | DE10297379T5 Kombinationstherapie zur Krankheitsbehandlung Combination therapy for the treatment of disease |
| 10/14/2004 | CA2734606A1 Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production |
| 10/14/2004 | CA2521050A1 Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
| 10/14/2004 | CA2520936A1 An antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
| 10/14/2004 | CA2520868A1 Staphylococcus epidermidis antigens |
| 10/14/2004 | CA2520671A1 Compositions and methods involving respiratory syncytial virus subgroup b strain 9320 |
| 10/14/2004 | CA2520386A1 Nontypeable haemophilus influenzae virulence factors |
| 10/14/2004 | CA2520381A1 Proteolytic and covalent antibodies |
| 10/14/2004 | CA2519958A1 Pharmaceutical composition comprising a macrolide immunomodulator |
| 10/13/2004 | EP1466925A1 Antibodies against fibroblast growth factor 23 |